2007
65-A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy (Protocol #CKI-301) NovaCardia, Inc. 2007.
2006
64- A Phase IIa, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety and Effect on Ventricular Rate of Multiple Oral Doses of YM758 in Adult Subjects with Atrial Fibrillation (Protocol # 758-CL-015) Astellas Pharma US, Inc. 2006.
63- A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia (Protocol # 20050222) Amgen Inc. 2006.
62- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Exploratory Efficacy Study of Sitaxsentan Sodium to Improve Impaired Exercise Tolerance in Subjects with Diastolic Heart Failure (Protocol # FDHF01) Encysive Pharmaceuticals, Inc. 2006.
61. A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with Mixed Dyslipidemia (Protocol # M05-758) Abbott Laboratories 2006.
60-A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Monotherapy in Subjects with Mixed Dyslipidemia (Protocol #M05-749) Abbott Laboratories 2006.
59-A Phase II, Multi-Center, Randomized, Double-Blind, Flexible Dose Study of ZP120 Administered as I.V. Infusion as Add-On Therapy in Patients with Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated with Furosemide (Protocol #A /S 05-025) Zealand Pharma 2006
2005
58. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients with NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels. (DITPA, Protocol #DIT-803) Titan Pharmaceuticals, Inc. 2005
57. A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG™ MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH). The CLEVER Study. (CLEVER, Protocol # SK&F-105517/100216) GlaxoSmithKline 2005
56. Endothelial dysfunction and its correlation with the 6-minute walk test in patients with chronic heart failure. (Protocol #FT-1) 2005
2004
55. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Three Doses of Caperitide in Subjects with Congestive Heart Failure/A Phase-2, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects with Congestive Heart Failure (Caperitide, Protocol #03-0-162) Astellas Pharma Us, Inc. 2004
54. A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study if the Effects of KW-3902, both as monotherapy and in combination with furosemide, on diuresis and renal function in patients with congestive heart failure (CHF) and renal impairment treated with oral loop diuretics who require hospitalization for fluid overload (Novacardia, Protocol #CKI-201) NovaCardia, Inc. 2004
53. A Multicenter trial of the Orqis Medical CRS for the ENhanced Treatment of CHF Unresponsive to Medical Therapy (MOMENTUM, Protocol #2003-C) Orqis Medical 2004
52. Follow-Up Serial Infusions of Natrecor (nesiritide) for the Management of Patients with Heart Failure FUSION II (Protocol #A034) Scios, Inc. 2004
2003
51. COMPASS-HF (Chronicle Offers Management of Patients with Advanced Signs and Symptoms of Heart Failure. Medtronic, Inc. 2003
50. Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure (EVEREST, Protocol 156-03-236) Otsuka Maryland Research Institute, Inc. 2003
49. A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects. (STARSHIP, Protocol # 4522US/007). AstraZeneca 2003
48. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients with Acute Heart Failure. (VERITAS-2, Protocol #AC-051-037). Actelion Pharmaceuticals, LTD 2003
47. A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of Vasogen’s immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure (ACCLAIM, Protocol #0202) Vasogen, Inc. 2003
2002
46. A Double-blind, Randomized, placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in subjects with Symptomatic Congestive Heart Failure (CHF) and Anemia. (STAMINA-HFP Protocol 20010170) Amgen. 2002
45. Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure-THE REVIVE STUDY. Protocol 3001069 Orion Pharma. 2002
44. African-American Heart Failure Trial (A-HeFT). Medifacts International (MIMC). 2002
43. The Studies of Oral Enoximone Therapy in Advanced Heart Failure. A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic heart Failure Subjects. (Study number My-021) – ESSENTIAL Myogen, Inc. 2002
42. A Phase II, Multi-Center, Double-Blinded, Placebo-Controlled, Dose Finding Efficacy and Safety Study of the A
1-Adenosine Receptor Agonist DTI-0009 Administered Intravenously to Patients with Atrial Fibrillation (IND #58, 614) Discovery Therapeutics International. 2002.
41. A Randomized, Double-blind, Placebo-Controlled, Dose–Ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients with Decompensated Chronic Heart Failure (Protocol #087-CL-071). Yamanouchi Pharma America, Inc. 2002.
2001
40. A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist (SR 121463B) on clinical improvement in patients with severe chronic heart failure. The AQUAVIT trial. Protocol #DFI4510. Sanofi- Synthelabo, Inc. 2001.
39. A Randomized, double-blind, comparator-controlled study of Pioglitazone HCL vs Glyburide with type 2 (non-insulin dependent) diabetes mellitus and mild to moderate CHF. (Takeda 504). Omnicare. 2001
38. A randomized, DB, comparator-controlled study of pioglitazone vs glyburide in the treatment of subjects w/type 2 (non-insulin dependent) diabetes mellitus & mild cardiac disease (NYHA I). (Takeda 520). Omnicare. 2001.
37. A multicenter, double-blind placebo-controlled, randomized trial to evaluate the effect of extended release Metoprolol succinate (Toprol-XLâ ) on cardiac remodeling in asymptomatic heart failure patients (NYHA class I) with left ventricular dysfunction. (REVERT) AstraZeneca. 2001.
36. A multicenter, multinational open clinical study to explore relationships between genotype (from DNA) and serologic (from serum) findings and phenotypic manifestations in a large cohort of participants. Protocol 99-302. GCI Genomics. 2001.
35. Assessment of the effect of brain natriuretic peptide on renal blood flow in patients with heart failure. Scios, Inc. 2001.
34. Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women with Prosthetic Heart Valves (Protocol #011008).
2000
33. A Double-Blind, Parallel-group, Multicenter, Randomized, Placebo Controlled, study to assess the Efficacy and Safety of Tezosentan in patients with Acute Heart Failure associated with Acute Coronary syndromes (ACS) (304). The RITZ V Trial. Actelion-Hesperion, Ltd. 2000.
1999
32. A Multicenter, Double-Blind, Placebo-controlled, Study of the Effects of Manoplax (Flosequinan), 75 mg Twice Daily or 10 mg Once Daily, for Sixteen Weeks on Duration of Exercise Treadmill Testing and Disease Symptoms in Congestive Heart Failure. The Boots Company, Inc. 1999.
31. Multi-center, Randomized, Double-Blind, Placebo-Controlled trial evaluating the safety and efficacy of Eplerenone in patients with Heart Failure following acute myocardial infraction. The EPHESUS Trial. 1999
30. Omapatrilat verses Enalapril, Randomized trial of utility in reducing events in reducing events. The OVERTURE Trial. Bristol Myers Squibb. 1999.
29. A double-blind, parallel-group, multi-center, Randomized, placebo-controlled study to assess the efficacy (symptomatology) and safety of RO-61-0612 (tezosentan) in patients with acute decompensation heart failure. The RITZ I and II Trials Actelion – Hesperion LTD. 1999.
28. A multicenter, randomized, double-blind placebo-controlled study of the hemodynamic and clinical effects of Natrecorâ (nesirtide) compared with nitroglycerin therapy for symptomatic decompensated CHF. The VMAC Trial. Scios Inc. 1999
27. Multicenter, Double-Blind, Randomized, Placebo Controlled, Phase II/III study of the efficacy and safety of recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFr:fc) (etanercept) in patients with chronic heart failure (class II-IV). The RENAISSANCE Trial. Immunex. 1999
26. Candesartan cilexetil in heart failure – Assessment of reduction in mortality/morbidity (Charm) study of Candesartin in patients with heart failure. The CHARM Trial.Astra Zeneca. 1999
25. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness. The ESCAPE Trial. National Heart, Lung and Blood Institute. 1999 Bio-Impedance cardiography in advanced heart failure. A Substudy of the Evaluation study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness. (ESCAPE). The BIG Trial. 1999
24. Multicenter, Randomized, Double Blind, Placebo-Controlled study of OPC-41061 to evaluate the effects of OPC-41061 on the acute and chronic outcomes of hospitalized patients with worsening congestive heart failure. Acute and Chronic therapeutic impact of a vasopressin antagonist in Congestive Heart Failure. The ACTIV-CHF Trial. Ostuka America Pharm, Inc. 1999
23. Six (6) Months multicenter, Double-Blind Placebo-Controlled parallel group design clinical study to assess efficacy/safety of 125 mg daily dose of Azimilide Dihydrochloride for treatment of Atrial Fibrillation in pts who require electrical cardioversion w/open-label follow-up phase to assess the long term efficacy and safety of 125 mg oral dose of Azimilide. The A-STAR Trial Protocol 2000038. Proctor & Gamble. 1999
22. A multicenter, six months, double-blind placebo controlled, parallel group design clinical study to assess the efficacy and safety of a daily oral dose of 125 mg of Azimilide Dihydrochloride for prophylactic treatment of atrial fibrillation & an open-label follow-up clinical phase to assess long-term efficacy /safety of a daily oral dose of 125 mg of Azimilide Dihydrochloride. The A-COMET Trial Protocol 2000037. Proctor & Gamble. 1999
1998
21. Transform7 system randomized clinical trial (Dynamic Cardiomyoplasty) (C-SMART).Medtronic 1998
20. Multicenter, randomized, double-blind, placebo-controlled, parallel trial to assess the effect of Valsartan on exercise capacity, quality of life and signs and symptoms, in patients with stable, chronic congestive heart failure (NYHA class II-IV).Novartis 1998
19. Inhibition of metallo protease by BMS-186716 in a randomized exercise and symptoms study in subjects with heart failure The IMPRESS Trial.Bristol Myers-Squibb 1998
18. A double-blind, placebo-controlled, parallel design study to determine the effect of 75 or 100 mg of orally administered azimilide dihydrochloride versus placebo on survival in recent post-myocardial patients at risk of sudden death The ALIVE Trial.Procter & Gamble 1998
17. A multicenter randomized double-blind, placebo-controlled study to determine the effect of carvedilol on mortality in patients with severe chronic heart failure. The COPERNICUS Trial.Smith Kline Beecham 1998
16. A randomized, double-blind, placebo-controlled, sequential-panel, single-dose study to investigate the acute hemodynamic effects of I.V. L-753,037 (BQ4508-2) in patients with symptomatic heart failure.Merck 1998
1997
15. MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure A Double-Blind, Placebo Controlled Survival Study with Metoprolol CR/XL in Patients with Decreased Ejection Fraction and Symptoms of Heart Failure. 1997
14. A randomized, open-label, active-controlled, multicenter phase III safety study of two doses of NATRECOR hBNP administered as a continuous infusion in the treatment of decompensated CHF. Scios 1997.
1996
13. A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of amlodipine on survival in patients with congestive heart failure. The PRAISE-2 Trial. Pfizer 1996
1995
12. A phase 3, randomized, double-blind, placebo-controlled evaluation of the acute and chronic efficacy and safety of OPC-18790 in the treatment of patients with decompensated heart failure. 1995
11. A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure. The VEST Trial. 1995.
1994
10. The Effect of RO-40-5967 on ETT Duration (6 Months) and on all Causes of Mortality in Comparison with Placebo in Patients with Chronic Heart Failure (NYHA Class II-IV) Treated for Approximately Three Years. The MACH-I Trial. F. Hoffman-La Roche Ltd. 1994
1993
09. A Randomized Multicenter Study Comparing the Efficacy and Safety of Intravenous Milrinone and Intravenous Nitroglycerin in Patients with Severe Congestive Heart Failure. Sanofi Winthrop. 1993
1992
08. Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Event. The CAPRIE Trial. Sterling-Winthrop. 1992
07. PRAISE I (Prospective Randomized Amlodipine Survival Evaluation). A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure. Pfizer Laboratories. 1992
06. A Multicenter, Double-Blind, Randomized, Parallel, Pilot Enalapril-controlled Study to Evaluate the Safety and Tolerability of Losartan in Patients with Symptomatic Heart Failure. Merck & Co., Inc. 1992
1991
05. A Multicenter, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Fosinopril in Patients with Decompensated Congestive Heart Failure. Bristol Myers Squibb. 1991
04. A Double-Blind, Placebo-Controlled, Crossover Study of the Effects of Intermittent Therapy with Transdermal Nitroglycerin in Patients with Chronic Congestive Heart Failure. Schering Plough. 1991
03. A Double-Blind, Randomized, Placebo-Controlled Study of the Effect of Flosequinan on the Survival of Patients with Chronic Congestive Heart Failure. Boots Pharmaceuticals. 1991
02. Captopril Plus TPA Following Acute Myocardial Infarction: A Double-Blind, Placebo-Controlled Study of the Effects on Left Ventricular Size and Function. Bristol Myers Squibb. 1991
01. Phase II, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Intravenous Milrinone in Left Ventricular Dysfunction in Patients With Congestive Heart Failure Following Acute Myocardial Infarction. Sterling-Winthrop Research Institute. 1990.
